{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzoyj2\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzoyj2\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/20\\\/17\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/20\\\/17\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/20\\\/17\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/20\\\/17\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EOverweight and obese patients without type 2 diabetes mellitus (T2DM) who were treated with liraglutide experienced a greater reduction in body weight and were more likely to revert to normoglycemia compared to those treated with placebo. This article presents data from a poster on the Effect of Liraglutide on Body Weight in Nondiabetic Obese Subjects or Overweight Subjects With Comorbidities\u2014Obesity and Prediabetes trial [SCALE; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01272219\u0026amp;atom=%2Fspmdc%2F14%2F20%2F17.atom\u0022\u003ENCT01272219\u003C\/a\u003E].\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eobesity\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ediabetes mellitus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ediabetes \u0026amp; endocrinology clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eprevention \u0026amp; screening\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eobesity\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003EOverweight and obese patients without type 2 diabetes mellitus (T2DM) who were treated with liraglutide experienced a greater reduction in body weight and were more likely to revert to normoglycemia compared to those treated with placebo. Xavier Pi-Sunyer, MD, MPH, Columbia University, New York, New York, USA, presented data from a poster on the Effect of Liraglutide on Body Weight in Nondiabetic Obese Subjects or Overweight Subjects With Comorbidities\u2014Obesity and Prediabetes trial [SCALE; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01272219\u0026amp;atom=%2Fspmdc%2F14%2F20%2F17.atom\u0022\u003ENCT01272219\u003C\/a\u003E].\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EObesity is associated with prediabetes, which substantially increases the risk of developing T2DM and related complications [Kasuga M. \u003Cem\u003EJ Clin Invest\u003C\/em\u003E 2006]. The SCALE trial was designed to evaluate the safety and efficacy of liraglutide on weight management. The purpose of this analysis was to evaluate the effect of liraglutide on weight loss and measurements of diabetes, including fasting and postload glucose, as well as the prevalence of prediabetes and the onset of T2DM.\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EIn the double-blind multicenter Phase 3 SCALE trial, 3731 patients without T2DM who were overweight or obese and had a body mass index (BMI) \u2265 27 kg\/m\u003Csup\u003E2\u003C\/sup\u003E and \u2265 1 comorbidity were randomly assigned to receive 3.0 mg of subcutaneous liraglutide or placebo for 56 weeks. Patients who received liraglutide were again randomly assigned to liraglutide or placebo for an additional 12 weeks, while patients receiving placebo remained on it. All patients were followed for an additional 2 weeks.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EPatients aged \u2265 18 years were eligible for the SCALE trial if they had a BMI \u2265 30 kg\/m\u003Csup\u003E2\u003C\/sup\u003E or \u2265 27 kg\/m\u003Csup\u003E2\u003C\/sup\u003E plus dyslipidemia or hypertension (treated or untreated) and stable body weight with a history of failed dietary effort to reduce it. Exclusion criteria were HbA\u003Csub\u003E1c\u003C\/sub\u003E \u2265 6.5%, fasting plasma glucose \u2265 126 mg\/dL, or a 2-hour postchallenge plasma glucose \u2265 200 mg\/dL at baseline. All patients were counseled to reduce their caloric consumption by 500 kcal\/day and to start an exercise program.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EPatients who had received liraglutide experienced a decrease in body weight of 8.0% (8.4 kg) over 56 weeks, compared with 2.6% (2.8 kg) in patients who received placebo, with an estimated treatment difference of \u22125.4% (\u22125.6 kg; 95% CI, \u22125.8% to \u22125.0%; p \u0026lt; .0001). In addition, a greater number of patients in the liraglutide arm experienced a weight loss over 56 weeks of \u2265 5% (estimated OR [EOR], 4.8; 95% CI, 4.1 to 5.6; p \u0026lt; .0001) and \u0026gt; 10% (EOR, 4.3; 95% CI, 3.5 to 5.3; p \u0026lt; .0001) compared with patients in the placebo arm.\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EPatients who had received liraglutide and were then randomly reassigned to placebo during the additional 12 weeks experienced weight gain compared with those who remained on liraglutide (estimated treatment difference, 2.2%; p \u0026lt; .0001). Liraglutide treatment improved fasting and postload glycemia compared with placebo, as measured by an oral glucose tolerance test, with patients with prediabetes experiencing a greater improvement than those without it.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EAt 56 weeks, 20.7% of patients in the placebo arm had progressed from normoglycemia to prediabetes compared with 7.2% of patients in the liraglutide arm (EOR, 3.3; logistic regression, p \u0026lt; .0001). Furthermore, 69.2% of patients in the liraglutide arm with prediabetes at baseline reverted to normoglycemia at 56 weeks, compared with 32.7% of the placebo arm (EOR, 4.85; p \u0026lt; .0001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EMore patients in the placebo arm developed T2DM compared with patients in the liraglutide arm (14 vs 4, respectively; EOR, 8.06; p = .0003). During the additional 12 weeks, patients randomly reassigned to placebo developed prediabetes more frequently compared with patients who remained on liraglutide.\u003C\/p\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EDr. Pi-Sunyer indicated that, in his opinion, the data from this analysis of the SCALE trial suggest that the addition of liraglutide to diet and exercise resulted in superior improvements in the prevalence of prediabetes, T2DM, and body weight compared with placebo.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/20\/17.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzoyj2\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}